Holding of core competence for precision medicine era The paradigm of future medicine in the fourth industrial revolution era is shifting with personalized “precision medicine” at the center. Theragen Etex group receives more attention because it has both gene analysis ability and personalized drug development capability, which are core technologies for “precision medicine.”

The world’s highest level of genome analysis technology Theragen Bio has made excellent achievements using innovative technologies such as the creation of the world’s first female/tiger/minke whale genome maps and completion of the first domestic human genome map, holding the largest domestic genome analysis performance, and first commercialization of individual genome analysis service in Asia. The company is now poised to benefit from the new growth engine.

International GMP certified facilities, stable manufacturing and supply of medicines Theragen Etex increased production facilities, acquired GMP certification from international consultative group, Pharmaceutical Inspection Cooperation/Scheme (PIC/S), and now stably manufactures and supplies medicines with its distribution affiliated companies. It also actively conducts research for securing a new drug pipeline such as incrementally modified drugs (IMD) or orphan drugs.

Carcinogenic gene analysis and development of novel anticancer drug With the cooperation of the world’s best research institutes and medical staff, we analyze variations in carcinogenic genes such as stomach cancer, liver cancer, head and neck cancers, and breast cancer and disease mechanisms. Vactosertib, a novel anticancer drug that we are developing, is under clinical trial in Korea and the US.